Nanotherapeutics files investigational new drug application for nanodox(tm) hydrogel to treat lower extremity diabetic ulcers

Nanotherapeutics Files Investigational New Drug Application for NanoDOX(TM) Hydrogel to Treat Lower Extremity Diabetic Ulcers September 04, 2008 08:50 AM Eastern Daylight Time Nanotherapeutics Files Investigational New Drug Application
for NanoDOX™ Hydrogel to Treat Lower Extremity Diabetic

ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, a privately held specialty biopharmaceutical company,announced today that it has submitted its first Investigational New Drug (IND) application to the FDA for a phase IIaclinical study for its product NanoDOX™ Hydrogel, a topical doxycycline hydrogel for chronic wounds. The randomizeddouble-blind study will assess the safety and efficacy of the product on the healing rates of non-infected diabetic ulcersof the lower extremity. Assuming FDA approval, the Company expects to complete enrollment in early 2009.
The phase IIa study will be conducted at Veterans’ Administration hospitals in Florida. The Company will enrolldiabetics, 18 and older, who have diabetic ulcers of the foot and lower limbs at the Gainesville and Lake City VAhospitals. The primary endpoint to evaluate the hydrogel’s efficacy will be the rate of complete (100%) wound closureduring a 20-week treatment period.
“Diabetic ulcers are the primary cause of amputations of the leg, foot, or toe. Two-thirds of all lower extremityamputations in the United States are directly linked to diabetes. We believe that NanoDOX™ is a unique formulation thatholds significant promise for the millions of people suffering from diabetic ulcers,” said Weaver H. Gaines, Chairman ofthe Board. “Filing the IND for the phase II study is a major step forward in our clinical program and demonstrates thestrength of our technology and our capability to generate unique new product opportunities.” NanoDOX™ Hydrogel, the company’s leading pharmaceutical product in development, is an alternative topicalformulation of doxycycline. Nanotherapeutics developed the product with its proprietary particle stabilization technologyand formulated it to improve the topical delivery of doxycycline to increase local efficacy of the drug.
Jim Talton, Ph.D., President of Nanotherapeutics, said, “The Company is also exploring the use of NanoDOX™Hydrogel for treating traumatic open wounds incurred in combat. In collaboration with Walter Reed Army Medical Center,we plan a clinical trial to evaluate safety and efficacy in treatment of deep trauma wounds. A separate IND will be filedfor this indication.” NanoDOX™ 1% Doxycycline Monohydrate Hydrogel
NanoDOX™ Hydrogel is a topical hydrogel applied directly to the entire surface of the wound. A gauze dressing or anon-adhering dressing is applied to cover the hydrogel and wound. This allows the hydrogel to provide a moist healingenvironment. NanoDOX™ Hydrogel is composed of doxycycline monohydrate, a currently marketed antibiotic availablein tablet and injectable forms.
Lower Extremity Diabetic Ulcers
There are more than 18 million people diagnosed with diabetes in the United States and about 5% of them will developfoot and lower limb ulcers. There are, however, about another 7 million diabetics who are undiagnosed. Foot and lowerleg ulcers are the primary cause of the approximately 80,000 amputations of toes, feet, and lower legs each year. It isestimated that up to 30% of diabetics with foot ulcers will eventually require amputation. (National Institutes of Healthand CDC data)…ignette.cachetoken&javax.portlet.endCacheTok=com.vignette.cachetoken Nanotherapeutics Files Investigational New Drug Application for NanoDOX(TM) Hydrogel to Treat Lower Extremity Diabetic Ulcers About Nanotherapeutics
Nanotherapeutics is a privately held specialty biopharmaceutical company with full product development and cGMPmanufacturing capabilities and a proprietary pipeline. The Company’s technologies can be used with all drug typesranging from small molecules to proteins and peptides. Nanotherapeutics is focused on drug development, not early-stage discovery. Its first FDA approved product, Origen™ DBM with Bioactive Glass, is an injectable bone graft fororthopedic applications. For more information, visit
NanotherapeuticsWeaver H. Gaines, 386-462-3961 or 917-862-2274Chairman of the Permalink:…ignette.cachetoken&javax.portlet.endCacheTok=com.vignette.cachetoken


Dean's executive leadership series - pepperdine university / dels 2008-2009

Dean's Executive Leadership Series - 2009-2010 Transcript of Presentation with John Figueroa, President of U.S. Pharmaceuticals for McKesson Corporation About DELS: The Dean's Executive Leadership Series at the s in-depth audio or video interviews with today's top business practitioners and thought leaders. e podcasts to hear their views and insight on the current challenge

Addendum instr.indd

ADDITIONAL INSTRUCTIONS 2.1 Check Brake Lines at hub 2.1.1 ChildPod® Rear Wheels may not install due to Brake Arm engagement during shipment 1. Remove Steering Limiter Bolt During shipping, the Brake Arm may engage and push the Cable Housing out of its Barrel Adjustor. End of Cable Housing must insert fully into its Barrel Adjustor to 20 mm or equivalent wrench required. 1. Steerin

Copyright ©2018 Sedative Dosing Pdf